In Stage I CRC (Figure 3A), expression of GPX4 (p = 0.87, HR: 1.07, 95%CI: 0.39–2.95) and FACL4 (p = 0.48, HR: 1.43, 95%CI: 0.52–3.98) have no prognostic role for OS, while patients with low level of NOX1 had worse survival outcomes (p = 0.03, HR: 1.07, 95%CI: 0.39–2.95). Here, ACSL4 is linked to colorectal carcinoma.